1 / 30

Rafael Laniado-Labor í n MD, MPH, FCCP

Rafael Laniado-Labor í n MD, MPH, FCCP. MD: Universidad Autónoma de Guadalajara, M éxico, 1975 MPH: Graduate School of Public Health, San Diego State University, 1990 Pulmonologist, Hospital General de Tijuana, Mexico, since 1984

mya
Download Presentation

Rafael Laniado-Labor í n MD, MPH, FCCP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rafael Laniado-Laborín MD, MPH, FCCP MD: Universidad Autónoma de Guadalajara, México, 1975 MPH: Graduate School of Public Health, San Diego State University, 1990 Pulmonologist, Hospital General de Tijuana, Mexico, since 1984 Professor, Facultad de Facultad de Medicina, Universidad Autónoma de Baja California since 1984 Fellow, American College of Chest Physicians rafaellaniado@gmail.com

  2. TB and the Mexican Border:BCG, Practices & Complications

  3. Introduction • Immunization with bacillus Calmette–Guerin (BCG) is currently used in many parts of the world as a means of preventing tuberculosis • It remains a highly controversial method of preventing TB despite more than 80 years of use

  4. BCG: History • BCG is named after the two French investigators responsible for developing the vaccine from an attenuated strain of Mycobacterium bovis. • They presented their results to the Academie de Sciences in 1908

  5. BCG: history • BCG vaccines are the oldest of the vaccines in wide use today, having been derived between 1906 and 1919 by in vitro attenuation of an isolate of Mycobacterium bovis.

  6. BCG: history • The product of this attenuation was never cloned, but was distributed to many laboratories, which then propagated the vaccine strain under different conditions • As a result, the bacteria marketed today by different providers as BCG are by no means bacteriologically identical Fine. Rev Inf Dis 1989; 11:S353

  7. BCG: history • BCG was first used as an antituberculosis vaccine in humans in 1921 • BCG vaccination was encouraged worldwide until these vaccine became –after the eradication of smallpox- the most widely used vaccine in the world • Only the US and the Netherlands have not used BCG on a national scale

  8. BCG History: The Lübeck disaster • Between 10 December 1929 and 30 April 1930, 251 of 412 infants born in Lübeck, Germany, received three doses of BCG vaccine by the mouth during the first ten days of life. • Of these 251, 72 died of tuberculosis, most of them in two to five months, and all but one before the end of the first year

  9. BCG History: The Lübeck disaster • In addition, 135 suffered from clinical tuberculosis but eventually recovered • 44 became tuberculin-positive but remained well • Of 251 children, 207 (82.5%) died or developed tuberculosis

  10. Expanded Program on Immunization (WHO) • In 1974 when EPI was launched by WHO, <5% of the world children were immunized against 5 infectious diseases including TB • By 1995, BCG had the highest vaccination coverage, 87%

  11. Is BCG effective?

  12. Is BCG effective? • Millions of people around the world have been vaccinated with BCG, but even so, the efficacy of the vaccine is uncertain.

  13. Is BCG effective? • Results of randomized controlled trials (RCT) and case control studies (CCS) showed the protective efficacy against tuberculosis as uncertain and unpredictable, as protective efficacy varied from 0 to 80%

  14. BCG: a meta-analysis • Meta-analysis of over 1,200 articles from international publications • Only 14 prospective trials and 12 case-control studies met the selection criteria JAMA 1994; 271:698-702

  15. BCG: a meta-analysis • Combining data from the trials the RR for TB among those vaccinated with BCG was 0.49 (95%CI, 0.34 to 0.70); protective effect 51% • Combining data from the case-control studies, the OR for BCG vaccination against TB was 0.50 (95%CI 0.39 to 0.64) JAMA 1994; 271:698-702

  16. BCG: a meta-analysis • Combining data from 7 trials the RR for death from TB among vaccinated was 0.29 (95%CI 0.16 to 0.53); 71% protective effect • 5 CC studies showed a protective effect against meningeal TB of 64% • 3 CC studies showed a protective effect against disseminated TB of 78% JAMA 1994; 271:698-702

  17. However, the protection afforded by BCG against pulmonary disease in both children and adults is not proven Clin. Infect. Dis. 1995; 20:982–991

  18. Factors contributing to variability in BCG efficacy • Genetic variability of the subjects vaccinated • Use of different strains of BCG for immunization • Use of different doses of vaccine • Different schedules of immunization

  19. BCG and tuberculin reactivity

  20. BCG and tuberculin reactivity • Interestingly, skin test reactivity resulting from vaccination does not correlate with protection against tuberculosis • Animal and human studies have shown that tuberculin reactivity after BCG vaccination is highly variable CID 2000;30(Suppl 3):S262

  21. Tuberculin sensitivity and the ability to prevent tuberculosis are separate phenomena • Postvaccinal tuberculin sensitivity does not predict efficacy. • In fact, there is a slight negative correlation. GW Comstock. CID 2000; 30:S250

  22. BCG and tuberculin reactivity • The type of BCG vaccine, the number of doses of vaccine, time lapsed since BCG vaccination, age at BCG vaccination, genetics of the host, exposure to NTM, and exposure to tuberculin can all influence tuberculin reactivity after BCG vaccination CID 2000;30(Suppl 3):S262

  23. There is no reliable method of distinguishing tuberculin reactions caused by vaccination with BCG from those caused by natural mycobacterial infections.

  24. In general, BCG given in infancy is unlikely to lead to a positive PDD response (induration of greater than 10 mm diameter) in later life • Thus, a positive PPD test result in a BCG vaccinated person probably indicates concurrent or previous TB infection

  25. Prevalence of tuberculosis infectionin schoolchildren from Tijuana, Mexico • 1,131 school children in Tijuana, Mexico • mean age 11.43 + 0.10 years • The proportion of immunized children with a positive tuberculin reaction was significantly higher than that of non-immunized children (p<0.001) Salud Publica Mex 1998;40:47

  26. Prevalence of tuberculosis infectionin schoolchildren from Tijuana, Mexico • The proportion of positive reactors in first grade was identical for both groups (46.4% vs. 47.7%) • By 9th grade, the proportion of positive reactors was significantly higher among the immunized subjects (69.7% vs. 49.9%) • Diameter of induration was positively correlated with age (r=0.16, p<0.001) Salud Publica Mex 1998;40:47

  27. It is usually prudent to consider “positive” reactions to 5 TU of PPD tuberculin in BCG vaccinated persons as indicating infection with M. tuberculosis, especially among persons from countries with a high prevalence of tuberculosis

  28. Because most persons who have received BCG are from high-prevalence areas of the world, it is important that vaccinated persons who have a positive reaction to a tuberculin skin test be evaluated for tuberculosis and treated accordingly MMWR 1996; 45:RR-4

  29. However..... • A study of a large group of contacts of several active cases of TB, showed that ignoring BCG history may lead to overuse of chemoprophylaxis • 18.3% of non-BCG contacts were offered chemoprophylaxis, whereas 43.8% of contacts who had received BCG were offered chemoprophylaxis (p < 0.001). Int J Tuberc Lung Dis 1998; 2:S149

More Related